Related Experiment Video
Updated: Jul 30, 2025

Live Imaging and Analysis of Muscle Contractions in Drosophila Embryo
Published on: July 9, 2019
Congenital disorder of glycosylation - one size does not fit all: a parent's perspective
1Assistant Research Professor of Surgery, Department of Plastic Surgery, School of Medicine, Indiana University-Purdue University Indianapolis (IUPUI), Medical Research and Library (IB), IB424A, 975 W. Walnut St, Indianapolis, IN 46202-5143, USA.
Insights
This article shares a parent's experience with PMM2-congenital disorder of glycosylation (PMM2-CDG). It details the journey from diagnosis and the impact of off-label epalrestat treatment.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Medicine
Background:
- PMM2-congenital disorder of glycosylation (PMM2-CDG) is a rare inherited metabolic disease.
- PMM2-CDG affects multiple organ systems, leading to significant developmental challenges.
- Current treatment options for PMM2-CDG are limited, with many therapies used off-label.
Purpose of the Study:
- To provide a parental perspective on living with PMM2-CDG.
- To describe the diagnostic journey for a child with PMM2-CDG.
- To evaluate the effects of off-label epalrestat treatment in a child with PMM2-CDG.
Main Methods:
- Qualitative research methodology.
- Parental narrative and case study approach.
- Observation and documentation of treatment effects.
Main Results:
- The parental journey involved significant emotional and logistical challenges.
- Epalrestat treatment showed potential benefits, though further research is needed.
- The study highlights the importance of patient and family experiences in understanding rare diseases.
Conclusions:
- PMM2-CDG presents a complex challenge for affected families.
- Off-label use of epalrestat warrants further investigation for PMM2-CDG.
- Parental insights are crucial for comprehensive rare disease management.
Abstract:
This article is written by the parent of a child living with PMM2-congenital disorder of glycosylation (abbreviated to PMM2-CDG). It provides a parental perspective of the journey taken from diagnosis to present day and details the effect of off-label treatment with epalrestat.
Related Concept Videos
Inborn Errors of Metabolism
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Pedigree Analysis
Diabetes Mellitus: Type 2 and Gestational
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...

